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Summary. Purpose: To use data from the Randomized
Aldactone Evaluation Study (RALES) to compare clinical
outcomes and costs as part of the assessment of the eco-
nomic implications of spironolactone treatment of advanced
heart failure.
Methods: RALES was a randomized, double-blinded,
placebo-controlled trial that enrolled participants who had
severe heart failure and a left ventricular ejection fraction
of no more than 35% and who were receiving standard ther-
apy, including an angiotensin-converting enzyme inhibitor,
a loop diuretic, and, in some cases, digoxin. We used a de-
cision analytic model that incorporated data from partici-
pants in RALES as well as cost data from five countries that
participated in the study. Costs were calculated for nonfatal
hospitalizations, ambulatory care, spironolactone therapy,
and death. The primary health outcome was quality-
adjusted life-years saved (QALYS). Outcomes were evalu-
ated for the first 35 months of observation in RALES.
Results: Spironolactone therapy during the first 35
months of follow-up in RALES increased quality-adjusted
survival time (0.13 QALYS, 95% CI, 0.07 to 0.18) without in-
creasing costs ($713 savings, 95% CI, $2123 savings to $783
in costs). Spironolactone therapy either dominated placebo
or had a ratio of cost per QALYS that was unlikely to ex-
ceed $20,300. These results were robust in both one-way
and multiway sensitivity analyses.
Conclusions: Even after implementation of current clin-
ical guidelines, addition of spironolactone therapy provides
an opportunity to further reduce the large clinical and eco-
nomic burden of patients with heart failure.
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Introduction
Congestive heart failure is a chronic, debilitating,
and inexorably progressive disease characterized by
significant morbidity and mortality. Despite advances
in the medical management of heart failure, the inci-
dence and prevalence of the disease continue to grow
[1]. In the United States alone, nearly 5 million peo-
ple are living with heart failure, and another 500,000
new cases are diagnosed each year [2]. The incidence of
heart failure approaches 10 per 1000 population after
the age of 65, and the 5-year mortality rate is approxi-
mately 50% [2].
Heart failure is also the most frequent and expensive
reason for hospitalization among people age 65 years
and older [3,4]. Each year in the United States, more
than 900,000 people are hospitalized for heart failure
and the direct costs of caring for all patients with heart
failure exceed $8 billion [5]. Total costs of treatment of
heart failure may approach $18 billion when evaluation
and long-term care are considered [5,6]. The incidence
and prevalence of heart failure in other industrialized
nations are similar to those in the United States [7].
Current evidence-based clinical practice guidelines
for the treatment of heart failure recommend an
angiotensin-converting enzyme (ACE) inhibitor and
a diuretic [8]. Recent studies of beta-blockers [9–12]
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and spironolactone [13] have shown that use of these
drugs may further reduce heart failure-related mor-
bidity and mortality. For example, the Randomized
Aldactone Evaluation Study (RALES) demonstrated a
30% reduction in the risk for death among patients with
advanced heart failure who were also receiving ACE
inhibitors, loop diuretics, and, in some cases, digoxin
[13].
Appropriate treatment of heart failure should im-
prove clinical outcomes and reduce morbidity-related
costs. In this study, we used data from RALES to
compare clinical outcomes and costs as part of the as-
sessment of the economic implications of spironolactone
treatment of advanced heart failure.
Methods
For this analysis, we adopted the structure of a previ-
ously published decision analytic model that we devel-
oped for the economic evaluation of the treatment trial
in the Studies of Left Ventricular Dysfunction (SOLVD)
[14]. We incorporated primary data from participants
in RALES as well as cost data from five countries that
participated in the study. Costs were calculated for non-
fatal hospitalizations, ambulatory care, spironolactone
therapy, and death. The primary health outcome was
quality-adjusted life-years saved (QALYS); secondary
health outcomes were years of survival according to
New York Heart Association (NYHA) functional class
and years of life saved. We evaluated incremental so-
cial costs (savings), expressed in 1999 U.S. dollars, and
health outcomes for the first 35 months of observation in
RALES (i.e., we adopted a truncated societal perspec-
tive that was limited to the evaluation of direct medical
costs).
Randomized aldactone evaluation study
RALES was a randomized, double-blinded, placebo-
controlled trial that enrolled 1663 participants with se-
vere heart failure (NYHA class III or IV with a his-
tory of class IV within the 6 months before enrollment)
and a left ventricular ejection fraction of no more than
35% who were receiving standard therapy, including
an ACE inhibitor and a loop diuretic, with or without
digoxin [13]. A total of 822 participants were randomly
assigned to receive 25 mg of spironolactone daily, and
841 were assigned to receive placebo. Participants were
enrolled in 195 centers in 16 countries. The primary
clinical end point was death from all causes; secondary
clinical end points included cardiovascular hospitaliza-
tions.
The trial was discontinued early, after a mean follow-
up of 24 months, because an interim analysis deter-
mined that spironolactone was efficacious. The study
showed that spironolactone was associated with a rel-
ative risk for death of 0.70 (95% confidence interval
[CI], 0.60 to 0.82; P< 0.001) compared with placebo. The
drug also had a relative risk for cardiac hospitalization
of 0.65 (95% CI, 0.54 to 0.77; P < 0.001). The design and
results of the study have been previously reported [13].
The model
Survival. Monthly survival probabilities for partic-
ipants receiving spironolactone and those receiving
placebo were estimated from Kaplan-Meier curves for
the first 35 months of observation in RALES. From
these curves we estimated the survival probabilities
at the beginning of months 1, 2, . . . , 36. We used the
trapezoidal method to estimate the area under the sur-
vival curve during each of the 35 months, e.g., ST t, j =
(St, j + St+1, j)/2, where ST t, j equals the survival time
(in months) in month t for patients who received treat-
ment j, St, j equals the proportion of patients who re-
ceived treatment j who were alive at the beginning of
month t, and St+1, j equals the proportion of patients
who received treatment j who were alive at the begin-
ning of month t + 1. These areas represented average
survival time during that month. The sum of these ar-
eas represented survival time during the 35 months of
RALES.
Functional status and quality-adjusted survival. At
each follow-up visit, NYHA classes of persons in the
study were evaluated by their physicians. We esti-
mated the proportion of time that study participants
were in each of the four NYHA classes during each
month.
Quality-adjusted survival was assessed by multiply-
ing our estimates of the number of years that study par-
ticipants spent in NYHA classes I through IV by a set
of quality-adjustment factors equaling 0.71, 0.61, 0.52,
and 0.47, respectively [14,15]. These factors were de-
rived from responses of 1601 participants in SOLVD
to a visual analogue scale, the Ladder of Life ques-
tionnaire. This questionnaire was used to rate current
health of persons in the four NYHA classes as a frac-
tion of healthy life (where 0 = worst possible life and
1 = best possible life).
Hospitalizations and deaths outside the hospital. We
estimated treatment-specific monthly probabilities of
nonfatal hospitalization conditional upon participants’
being available for follow-up in a month from data on
hospitalizations that were recorded prospectively dur-
ing the trial. To do so, we counted the number of hospi-
talizations in a month and divided the total by the total
follow-up time (in months) in the month. Figure 1 shows
the monthly probabilities of all-cause nonfatal hospital-
izations. Probabilities were estimated for each of eight
primary reasons for admission (atrial flutter, angina,
heart failure, myocardial infarction, stroke, ventricular
arrhythmia, other cardiovascular conditions, and other
noncardiovascular conditions). Total hospitalizations
during the 35 months of follow-up were estimated by
multiplying the monthly probabilities by the survival
time in a month.
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Fig. 1. Nonfatal hospitalization rates during the first 35
months of the Randomized Aldactone Evaluation Study
(RALES). Dashed line represents rates for patients receiving
spironolactone; solid line represents rates for patients receiving
placebo.
We also estimated monthly probabilities of death
both within (by cause) and outside the hospital.
Ambulatory care. Data on the use of outpatient ser-
vices were not recorded in RALES. We thus used
responses of 2704 family and general practitioners,
internists, and cardiologists to an American Heart
Association survey on outpatient management of par-
ticipants with heart failure [16] to estimate this uti-
lization. We assumed that physicians saw participants
four times a year; measured electrolytes three times
a year; and used standard chest radiography, echocar-
diography, radionuclide ventriculography, and exercise
testing less than once a year.
Spironolactone dose. To calculate the probability that
participants took 12.5, 25, and 50 mg of spironolactone
per day during each month of the trial, we used data
from case report forms that recorded prescribed study
medication and changes in this medication.
Cost data
Costs were estimated for eight types of nonfatal and
fatal hospitalization, deaths outside the hospital, am-
bulatory care, and spironolactone therapy itself. Daily
costs of hospitalizations (by reason for admission) were
derived from Belgium, Brazil, France, Spain, and the
United Kingdom (these five countries enrolled 1165
out of the 1663 [70%] participants in the trial). To esti-
mate per-patient total hospital costs in these countries,
we multiplied days in the hospital (by reason for ad-
mission) by the admission-specific daily cost estimates.
To estimate hospitalization costs for other developing
countries (Mexico, South Africa, and Venezuela), we
multiplied days in the hospital by the daily cost esti-
mates derived in Brazil. To estimate costs for other de-
veloped countries (Australia, Canada, Germany, Japan,
the Netherlands, New Zealand, Switzerland, and the
United States), we multiplied days in the hospital by
the admission-specific average of cost estimates from
Belgium, France, Spain, and the United Kingdom.
We estimated that death outside of the hospital
would cost $1000 and that this cost included the costs
of an ambulance, emergency services, and emergency
department care [14]. A year of ambulatory care was
estimated to cost $436 [14].
The cost of spironolactone therapy was based on
the U.S. average wholesale price ($48.30 per 100 25-mg
tablets).
Economic analysis
We present undiscounted and discounted years of sur-
vival (overall and by NYHA class), discounted years of
survival adjusted for the quality of survival, and dis-
counted costs. When one therapy dominated another
(i.e., had lower costs and greater QALYS), we report
this fact. When costs of care and QALYS were greater
for one therapy, we report ratios of discounted cost per
discounted QALYS. We used a discount rate of 3% [17].
We used a bootstrap procedure to assess stochastic
uncertainty in the analysis [18]. The model was repli-
cated 1000 times, and we report confidence intervals
for our estimates of undiscounted survival, discounted
survival, discounted QALYS, discounted costs, and the
ratio of cost per QALYS. We also used the results of the
bootstrap procedure to estimate the probability that
spironolactone has a cost-effectiveness ratio that falls
below $20,000 per QALYS.
Sensitivity analyses
Effects of five assumptions used in the models were
tested in one-way sensitivity analysis by varying the
following data: (1) the survival benefit (±33%), based
on the 95% CI for the relative risk for death among the
participants who received spironolactone; (2) the costs
of spironolactone (±50%); (3) the daily costs of hospital-
ization (±50%); (4) ambulatory care costs (±50%); and
(5) the discount rate, at 0% and 7%.
In the primary analysis, the QALYS results were
driven by heart failure class, not by side effects such as
gynecomastia (which was reported in 10% of patients
receiving spironolactone and 1% of placebo recipients
[13]). To address the ways in which gynecomastia may
affect quality of life, we performed a sensitivity anal-
ysis that assumed that (1) gynecomastia had an addi-
tive quality-adjustment factor of −0.10 (e.g., someone
in NYHA class I who experienced gynecomastia would
have had a quality-adjustment factor of 0.61 [0.71 minus
0.10]), and (2) patients who developed this side effect
experienced it for the duration of the trial.
Finally, we report best-case and worst-case scenar-
ios by combining the values of variables that led to
more optimistic results for spironolactone as well as
those that led to more pessimistic results. For the
best case, we assumed an increased survival benefit
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of +33%, decreased spironolactone costs (−50%), de-
creased hospital costs (−50%), decrease ambulatory
care costs (−50%), and a lower discount rate (0%). For
the worst case, we assumed a reduced survival bene-
fit (−33%), increased spironolactone costs (+50%), in-
creased hospital costs (+50%), increased ambulatory
care costs (+50%), a higher discount rate (7%), and a
quality-adjustment factor for gynecomastia (−0.10).
For each analysis, we report the impact of the
change in the assumption on the point estimates of dis-
counted costs, discounted years of life saved, discounted
QALYS, and the ratio of discounted cost per discounted
QALYS. We also report the impact of the change on
the 95% CI for the ratio of cost per QALYS. The confi-
dence intervals reflect both the uncertainty related to




Estimates of survival time during the first 35 months of
follow-up in RALES (overall and by NYHA class) are
reported in Table 1. Average survival time for partici-
pants who received spironolactone was 2.28 years (95%
CI, 2.01 to 2.34 years), which was 0.22 year (95% CI, 0.11
to 0.30 year) longer than the 2.07 years (95% CI, 1.86
to 2.13 years) of survival time among participants who
received placebo. In addition to lengthening survival,
spironolactone therapy also led to improved functional
status. Of the 0.22-year increase in survival, 0.05 year
was spent in NYHA class I and 0.13 year was spent
in NYHA class II; there was also a small substitution
of survival time between classes III and IV. Given the
short time horizon of the study and a discount rate of
3%, results for discounted survival time were similar to
those for undiscounted time.
Table 1. Years of survival for participants treated with spironolactone or placebo during the first 35 months of the randomized
aldactone evaluation studya
New York Heart Association Class
Variable I II III IV Totala 95% Confidence interval
Within-trial
Undiscounted years of life
Spironolactone 0.21 0.94 0.99 0.15 2.28 2.01 to 2.34
Placebo 0.16 0.81 0.93 0.17 2.07 1.86 to 2.13
Difference 0.05 0.13 0.06 −0.02 0.22 0.11 to 0.30
Discounted years of lifeb
Spironolactone 0.20 0.92 0.96 0.15 2.23 1.97 to 2.28
Placebo 0.15 0.79 0.91 0.17 2.02 1.82 to 2.08
Difference 0.05 0.13 0.05 −0.02 0.21 0.11 to 0.29
Discounted quality-adjusted years of lifeb
Spironolactone 0.14 0.56 0.50 0.07 1.27 1.12 to 1.30
Placebo 0.11 0.48 0.47 0.08 1.14 1.02 to 1.18
Difference 0.03 0.08 0.03 −0.01 0.13 0.07 to 0.18
aDifferences due to rounding.
bDiscount rate = 3% per year.
Because of the relatively large diminutions in the
quality-adjustment factors associated with survival
time in the four NYHA classes, discounted quality-
adjusted survival time was substantially less than dis-
counted survival time. Patients who received spirono-
lactone experienced 1.27 QALYS (95% CI, 1.12 to 1.30
QALYS) during the 35 months of follow-up; those who
received placebo experienced 1.14 QALYS (95% CI,
1.02 to 1.18 QALYS). Thus, spironolactone therapy was
associated with a gain of 0.13 discounted QALYS (95%
CI, 0.07 to 0.18 QALYS).
Costs
Table 2 shows the discounted costs for participants re-
ceiving either spironolactone or placebo for the first 35
months of follow-up in RALES. Costs were $8762 (95%
CI, $7612 to $9860; data not shown in table) for partici-
pants who received spironolactone and $9475 (95% CI,
$8197 to $10,434; data not shown in table) for placebo
recipients. The apparent cost saving of $713 (95% CI,
$2123 in savings to $783 cost) associated with spirono-
lactone therapy was not statistically significant (one-
tailed P = 0.2).
Cost-effectiveness
Figure 2 shows the distribution of the bootstrap repli-
cates comparing costs and QALYS among participants
who received spironolactone or placebo. The point esti-
mate indicates that spironolactone therapy dominated
placebo (i.e., it saved $713 and lengthened discounted
quality-adjusted survival time by 0.13 year). A total of
80.4% of the bootstrap replicates fell in the dominant,
southeast quadrant of the cost-effectiveness plane [19],
and 19.6% of the replicates fell in the northeast quad-
rant (in which spironolactone therapy increases costs
and discounted QALYS). The 95% CI for the compari-
son of costs and QALYS indicated that spironolactone
Economic Evaluation of RALES 57
Table 2. Costs by category for participants treated with spironolactone or placebo during the first 35 months of the randomized
aldactone evaluation studya
Variable Spironolactone Placebo Differenceb 95% Confidence interval
Nonfatal hospitalization 6096 7109 −1012 −2305 to 368
Fatal hospitalization 1113 1241 −128 −597 to 377
Deaths outside hospital 178 265 −86 −131 to −30
Ambulatory care 948 861 87 44 to 119
Spironolactone 427 0 427 377 to 441
Total cost 8762 9475 −713 −2123 to 783
aDiscount rate = 3% per year.
bDifferences due to rounding.
Fig. 2. 1000 bootstrap replicates of incremental costs and
quality-adjusted life-years saved (QALYS) during the first 35
months of the Randomized Aldactone Evaluation Study
(RALES).
may have dominated placebo (lower limit) or may have
had a cost per QALYS ratio as high as $6650 (upper
limit). The probability approaches 100% that the cost
per QALYS ratio was less than $20,000 (represented by
the fact that none of the replicates were above and to the
left of the line representing a ceiling ratio of $20,000).
Sensitivity analysis
Sensitivity analyses reported in Table 3 indicate that
our results were robust for the six variables we eval-
uated in one-way sensitivity analysis. In all cases, the
point estimate indicated that spironolactone dominated
placebo; in all cases the lower limit of the 95% CI for the
comparison of costs and QALYS indicated that spirono-
lactone dominated placebo, and in no case was the upper
limit of the 95% CI above $9050 (it equaled this value
when we reduced the survival benefit of spironolactone
by 33%).
Our sensitivity analysis evaluating diminutions in
preferences related to the development of gynecomas-
tia indicated that this condition might reduce the incre-
mental QALYS associated with spironolactone by 0.02,
from 0.13 to 0.11. The resulting 95% CI for the differ-
ence ranged from 0.05 to 0.16 (data not shown in table).
As with all of the other sensitivity analyses, the point
estimate and lower limit of the 95% CI indicated that
spironolactone dominated placebo; the upper limit of
the ratio was no higher than $8050 per QALYS.
Results of the multiway best- and worst-case sensi-
tivity analyses also indicated that the results were ro-
bust. In the best case, the point estimate and the lower
limit of the 95% CI suggested that spironolactone dom-
inated placebo, whereas the upper limit was $2400. In
the worst-case analysis, the point estimate and lower
limit of the 95% CI indicated that spironolactone dom-
inated placebo, while the upper limit of the ratio was
$20,300 per QALYS.
Discussion
Spironolactone therapy during the first 35 months of
followup in RALES increased quality-adjusted sur-
vival time (0.13 QALYS, 95% CI, 0.07 to 0.18) without
increasing costs ($713 savings, 95% CI, $2123 savings
to $783 in costs). Spironolactone therapy either domi-
nated placebo or had a ratio of cost per QALYS that was
unlikely to exceed $20,300. These results were robust
in both one-way and multi-way sensitivity analysis.
Spironolactone therapy also reduced the burden of
heart failure related to hospitalizations. This finding is
one of the primary reasons that spironolactone, in addi-
tion to treatment with an ACE inhibitor, loop diuretic,
and, in some cases, digoxin, appears to be economically
attractive for patients with severe heart failure.
Comparisons with economic results of other heart
failure treatments should be made with caution. For in-
stance, patients with less severe disease may not be as
responsive to spironolactone therapy as patients with
a more severe condition (or vice versa). In addition, dif-
ferences in mortality- and morbidity-related costs may
be associated with varying severity of heart failure.
Therefore, the effectiveness of spironolactone treat-
ment among patients with less severe disease requires
further study.
Patients with less severe disease may be more
affected by, or less tolerant of, the adverse effects of
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Table 3. Sensitivity analysis
Variable Disc costs Disc YOLS Disc QALYS Cost/QALYS 95% Confidence interval
Principal analysis −715 0.21 0.13 Dom+ Dom+ to 6650
Survival benefit
−33% −750 0.14 0.09 Dom+ Dom+ to 9050
+33% −680 0.28 0.17 Dom+ Dom+ to 5800
Spironolactone costs
−50% −925 0.21 0.13 Dom+ Dom+ to 4850
+50% −500 0.21 0.13 Dom+ Dom+ to 8750
Hospitalization costs
−50% −145 0.21 0.13 Dom+ Dom+ to 5300
+50% −1285 0.21 0.13 Dom+ Dom+ to 8400
Gynecomastia
−0.1 Quality-adjustment −715 0.21 0.11 Dom+ Dom+ to 8050
Ambulatory care costs
−50% −755 0.21 0.13 Dom+ Dom+ to 6350
+50% −670 0.21 0.13 Dom+ Dom+ to 7000
Discount rate
0% −750 0.22 0.14 Dom+ Dom+ to 6350
7% −665 0.20 0.12 Dom+ Dom+ to 7000
Multi-way sensitivity analysis
Best case −415 0.29 0.18 Dom+ Dom+ to 2400
Worst case −1020 0.13 0.07 Dom+ Dom+ to 20,300
+Results rounded to the nearest $5 (discounted costs), 0.01 (discounted years of life saved [YOLS] and quality-adjusted years of life saved [QALYS]), and
$50 (cost/QALYS). Disc = discounted; Dom+ = spironolactone dominates placebo.
therapy. In RALES, gynecomastia occurred in 10%
of the spironolactone-treated patients vs 1% of the
placebo recipients (P< 0.001). Other adverse reac-
tions related to spironolactone include digestive con-
ditions (gastric bleeding, ulceration, diarrhea, nausea,
and vomiting) and other endocrine effects (in addition
to gynecomastia), including inability to achieve or main-
tain erection, irregular menses or amenorrhea, and
postmenopausal bleeding (Aldactone Package Insert,
G.D. Searle & Co., Chicago, Illinois, 1998). Spirono-
lactone also carries a warning because it has been
shown to be a tumorigen in long-term toxicity studies,
prompting the recommendation that unnecessary use
of this drug should be avoided. while this side effect
profile may limit patients’ acceptance of the therapy,
these potential adverse outcomes should be weighed
against spironolactone’s positive effects on both mor-
bidity and mortality among patients with severe heart
failure.
Our study had several limitations. First, there were
substantial amounts of censored data in RALES, prin-
cipally because patients were enrolled over a period
of 21 months, and all follow-up stopped on August 24,
1998. This type of censoring generally falls under the
category of “missing completely at random,” which has
been referred to by Rubin as MCAR [20]. To address
the potential problems posed by such censoring, for
our analysis we adopted a method similar to the one
proposed by Lin et al. (referred to as the Lin interval
method) [21]. This method has been shown to be reli-
able in the face of missing data mechanisms that are
MCAR [21].
Second, our QALYS results were driven by heart
failure class, not by preference data collected directly
in the trial, because the trial did not assess preferences.
We used sensitivity analysis to address the QALYS
diminutions that may be associated with gynecomas-
tia. We found that even if the quality-adjustment
factor associated with gynecomastia was as high as
0.10, it had little impact on the cost-effectiveness of
spironolactone.
Third, we used average variable costs per day of
hospitalization to estimate hospital costs. We did not
have data indicating whether the intervention affected
the intensity of hospitalization. When we addressed this
issue through the sensitivity analysis related to the cost
of hospitalization, however, we found that it probably
had little effect on our results.
Fourth, we had no direct measurement of the costs
of ambulatory care, and we accounted only for differ-
ences in these costs that were associated with spirono-
lactone’s longer survival time. As with the cost of hospi-
talizations, sensitivity analysis indicated this variable
probably had little effect on our results.
Our results indicate that even after implementation
of current clinical guidelines, there are opportunities to
further reduce the large clinical and economic burden
of patients with heart failure. Spironolactone therapy
increased quality-adjusted survival and may have re-
duced the cost of treatment of advanced heart failure,
but the latter difference was not significant. Additional
study may be required to confirm these findings and
evaluate the cost-effectiveness of this drug in patients
with less severe disease.
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